The evolving landscape of tissue‐agnostic therapies in precision oncology

• Published in: CA: a cancer journal for clinicians Vol. 74; no. 5; pp. 433 - 452
• Main Authors: Subbiah, Vivek, Gouda, Mohamed A., Ryll, Bettina, Burris, Howard A., Kurzrock, Razelle
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.09.2024
• Subjects: Biomarkers; Biomarkers, Tumor - genetics; ErbB-2 protein; FDA approval; Genomics; Humans; Immune checkpoint inhibitors; Immunohistochemistry; Immunosuppressive agents; Immunotherapy; Immunotherapy - methods; Medical Oncology - methods; Medical Oncology - trends; Microsatellite instability; Mismatch repair; Molecular Targeted Therapy - methods; Neoplasms - drug therapy; Neoplasms - genetics; Neoplasms - therapy; Oncology; Pediatrics; Pembrolizumab; Precision medicine; Precision Medicine - methods; precision oncology; Solid tumors; targeted therapy; tissue‐agnostic therapy; Tumors; tumor‐agnostic drug development; United States > US; precision oncology; targeted therapy; tissue‐agnostic therapy; tumor‐agnostic drug development; immunotherapy
• ISSN: 0007-9235; 1542-4863; 1542-4863
• DOI: 10.3322/caac.21844

ABSTRACT Tumor‐agnostic therapies represent a paradigm shift in oncology by altering the traditional means of characterizing tumors based on their origin or location. Instead, they zero in on specific genetic anomalies responsible for fueling malignant growth. The watershed moment for tumor‐agnostic therapies arrived in 2017, with the US Food and Drug Administration's historic approval of pembrolizumab, an immune checkpoint inhibitor. This milestone marked the marriage of genomics and immunology fields, as an immunotherapeutic agent gained approval based on genomic biomarkers, specifically, microsatellite instability‐high or mismatch repair deficiency (dMMR). Subsequently, the approval of NTRK inhibitors, designed to combat NTRK gene fusions prevalent in various tumor types, including pediatric cancers and adult solid tumors, further underscored the potential of tumor‐agnostic therapies. The US Food and Drug Administration approvals of targeted therapies (BRAF V600E, RET fusion), immunotherapies (tumor mutational burden ≥10 mutations per megabase, dMMR) and an antibody‐drug conjugate (Her2‐positive–immunohistochemistry 3+ expression) with pan‐cancer efficacy have continued, offering newfound hope to patients grappling with advanced solid tumors that harbor particular biomarkers. In this comprehensive review, the authors delve into the expansive landscape of tissue‐agnostic targets and drugs, shedding light on the rationale underpinning this approach, the hurdles it faces, presently approved therapies, voices from the patient advocacy perspective, and the tantalizing prospects on the horizon. This is a welcome advance in oncology that transcends the boundaries of histology and location to provide personalized options.